Cross-reactive antibodies after SARS-CoV-2 infection and vaccination

Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Grobben, Marloes, van der Straten, Karlijn, Brouwer, Philip JM, Brinkkemper, Mitch, Maisonnasse, Pauline, Dereuddre-Bosquet, Nathalie, Appelman, Brent, Lavell, AH Ayesha, van Vught, Lonneke A, Burger, Judith A, Poniman, Meliawati, Oomen, Melissa, Eggink, Dirk, Bijl, Tom PL, van Willigen, Hugo DG, Wynberg, Elke, Verkaik, Bas J, Figaroa, Orlane JA, de Vries, Peter J, Boertien, Tessel M, Bomers, Marije K, Sikkens, Jonne J, Le Grand, Roger, de Jong, Menno D, Prins, Maria, Chung, Amy W, de Bree, Godelieve J, Sanders, Rogier W, van Gils, Marit J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Immunology and Inflammation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610423/
https://www.ncbi.nlm.nih.gov/pubmed/34812143
http://dx.doi.org/10.7554/eLife.70330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610423/
https://www.ncbi.nlm.nih.gov/pubmed/34812143
http://dx.doi.org/10.7554/eLife.70330

Ejemplares similares